CHARLOTTE, N.C. (AP) - Charlotte-based drug development company Chelsea Therapeutics has agreed to be acquired by a Danish pharmaceutical company for up to $658 million.
The Charlotte Observer reports (https://bit.ly/SEHqyr) that the transaction follows the Food and Drug Administration’s approval in February of Chelsea’s medication for treating dizziness and fainting in adults.
Chelsea is an early-stage drug development company. Lundbeck is planning to buy all outstanding shares of Chelsea for up to $7.94 a share, a 59 percent premium of the company’s closing price on Wednesday.
Northera is a medication meant to treat people suffering from dizziness, fatigue, and fainting upon standing in adults with Parkinson’s disease, multiple-system atrophy and other neurological disorders.
The deal is expected to close in the third quarter this year. Lundbeck is financing the acquisition with cash on hand.
Please read our comment policy before commenting.